MXPA03009644A - Grupos azabiciclicos sustituidos para el tratamiento de enfermedades. - Google Patents

Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.

Info

Publication number
MXPA03009644A
MXPA03009644A MXPA03009644A MXPA03009644A MXPA03009644A MX PA03009644 A MXPA03009644 A MX PA03009644A MX PA03009644 A MXPA03009644 A MX PA03009644A MX PA03009644 A MXPA03009644 A MX PA03009644A MX PA03009644 A MXPA03009644 A MX PA03009644A
Authority
MX
Mexico
Prior art keywords
disease
treatment
receptor antagonists
substituted azabicyclic
acethylcholine receptor
Prior art date
Application number
MXPA03009644A
Other languages
English (en)
Spanish (es)
Inventor
Jon E Jacobsen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MXPA03009644A publication Critical patent/MXPA03009644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA03009644A 2001-04-19 2002-04-18 Grupos azabiciclicos sustituidos para el tratamiento de enfermedades. MXPA03009644A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28495001P 2001-04-19 2001-04-19
US34890401P 2001-10-26 2001-10-26
PCT/US2002/008268 WO2002085901A1 (en) 2001-04-19 2002-04-18 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)

Publications (1)

Publication Number Publication Date
MXPA03009644A true MXPA03009644A (es) 2004-01-29

Family

ID=26962909

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009644A MXPA03009644A (es) 2001-04-19 2002-04-18 Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.

Country Status (11)

Country Link
US (1) US6869946B2 (enExample)
EP (1) EP1389208B1 (enExample)
JP (1) JP2004526788A (enExample)
AR (1) AR035817A1 (enExample)
AT (1) ATE314367T1 (enExample)
CA (1) CA2439960A1 (enExample)
DE (1) DE60208366T2 (enExample)
ES (1) ES2254723T3 (enExample)
MX (1) MXPA03009644A (enExample)
PE (1) PE20021019A1 (enExample)
WO (1) WO2002085901A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) * 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
CA2476681A1 (en) * 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
AU2003283648A1 (en) * 2002-12-06 2004-06-30 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
KR20050092777A (ko) * 2003-01-22 2005-09-22 파마시아 앤드 업존 캄파니 엘엘씨 알파-7 ｎＡＣｈ 수용체 전체 작용물질을 사용하는 질병의치료
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
WO2005063767A2 (en) 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
US20050234095A1 (en) 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
EP1736156A4 (en) * 2004-04-15 2010-06-16 Eisai R&D Man Co Ltd COMPOSITION CONTAINING 4-AMINO-5-CHLORO-N-¬ (1R, 3R, 5S) -8-METHYL-8-AZABICYCLO-3.2.1 OCT-3-YL-2-β-methyl-2-ynyloxy BENZAMIDE STABILIZED
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
US7632831B2 (en) 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
RU2418797C2 (ru) 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
DE602006017235D1 (de) * 2005-08-22 2010-11-11 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP5232374B2 (ja) * 2006-09-29 2013-07-10 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 ２位に置換基を有する光学活性キヌクリジノール類の製造方法
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2300012A4 (en) * 2008-05-23 2011-07-06 Univ South Florida METHOD FOR TREATING PERIPHERAL SENSORY NERVE LOSS WITH COMPOUNDS WITH NICOTIC ACIDYLCHOLINE RECEPTOR EFFECT
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5749797B2 (ja) 2010-05-17 2015-07-15 フォルム ファーマシューティカルズ、インコーポレイテッド （ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
EP3623371A1 (en) * 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN109320510B (zh) * 2018-11-27 2021-04-27 江苏慧聚药业有限公司 一种马罗匹坦游离碱的制备方法
CN111793017B (zh) * 2019-04-04 2024-01-16 广东东阳光药业股份有限公司 一种内酰胺化合物的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
FI763021A7 (enExample) 1975-11-03 1977-05-04 Thomae Gmbh Dr K
FR2529548A1 (fr) 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE385517T1 (de) 1985-03-14 1991-07-25 Beecham Group p.l.c., Brentford, Middlesex Arzneimittel zur behandlung von erbrechen.
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
EP0235878A3 (en) 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds
US4717563A (en) 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
NL8701682A (nl) 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
EP0272052B1 (en) 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides
US5237066A (en) 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
FR2625678B1 (fr) 1988-01-13 1991-06-07 Delalande Sa Agents anorexigenes a base de n-(quinuclidin-3-yl)-benzamides ou thiobenzamides
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de) 1988-03-29 1989-10-19 Sandoz Ag Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
ATE85217T1 (de) 1988-08-04 1993-02-15 Synthelabo Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.>oct-3-yl)benzamide und thiobenzamide.
US4920227A (en) 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US5290938A (en) 1989-09-15 1994-03-01 Chiron Laboratories A.S. Preparation of S-(-)- and R-(+)-N-(quinuclidinyl-3)-amide
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
CA2155330C (en) 1993-03-08 2002-01-29 Kathryn J. Elliott Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5723103A (en) 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
ES2202855T3 (es) 1997-04-18 2004-04-01 Janssen Pharmaceutica Nv Uso de antagonistas 5ht3 para promover el lavado intestinal.
WO2000073431A2 (en) 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Methods and compositions for measuring ion channel conductance
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20030055043A1 (en) 2003-03-20
AR035817A1 (es) 2004-07-14
DE60208366D1 (de) 2006-02-02
EP1389208A1 (en) 2004-02-18
ATE314367T1 (de) 2006-01-15
WO2002085901A8 (en) 2003-12-24
WO2002085901A1 (en) 2002-10-31
CA2439960A1 (en) 2002-10-31
PE20021019A1 (es) 2002-11-13
ES2254723T3 (es) 2006-06-16
US6869946B2 (en) 2005-03-22
JP2004526788A (ja) 2004-09-02
DE60208366T2 (de) 2006-07-06
EP1389208B1 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
ZA200203252B (en) Process for preparing 4"-substituted-9-deoxo-9A-AZA-9A-homoerythromycina derivatives.
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
IL161157A0 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
MXPA03008853A (es) Antagonistas de ccr5 utiles para el tratamiento del sida.
EP1449851A4 (en) NEUTRALIZING ANTIBODIES OF IL13 ALPHA RECEPTOR 1
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL153427A0 (en) 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
AU5497000A (en) Non-malignant disease treatment with ras antagonists
ZA200108392B (en) Process for the preparation of substituted pyrimidines.
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
MXPA03006606A (es) Proceso para preparacion de analogos de indeno heterociclico.
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
WO2000007544A3 (en) Vitronectin receptor antagonists
EG23417A (en) Process for the preparation 7 a-methylsteroids.
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
AU6523200A (en) Vitronectin receptor antagonists useful for the treatment of strokes
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
ZA991576B (en) Process for the preparation of substituted pyridines.